Skip to main content
SpringerLink
Log in

Treatment of Early Unfavorable HL

  • Chapter
  • First Online:
Hodgkin Lymphoma

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 1557 Accesses

Abstract

Early unfavorable or intermediate-stage Hodgkin lymphoma usually includes patients in stages I and IIA with clinical risk factors such as large mediastinal mass, extranodal disease, high ESR, or more than three or four nodal areas involved. In addition, selected stage IIB patients are also included in this risk group. The current treatment for these patients is based on four cycles of ABVD chemotherapy followed by involved-field radiotherapy. A more aggressive approach with two cycles of BEACOPP escalated followed by two cycles of ABVD has recently shown better tumor control but no advantage in overall survival yet. More cycles of chemotherapy have not resulted in better outcome in early unfavorable patients. One of the major current controversies in this risk group is the use of PET to guide treatment intensity or the use of additional radiotherapy in PET-negative patients. This chapter will give you an overview on the past and current treatment approaches and will highlight the discussion on PET-guided treatment in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: cotswolds meeting. J Clin Oncol 7(11):1630–1636

    CAS  PubMed  Google Scholar 

  2. Kostakoglu L, Cheson BD (2014) Current role of FDG PET/CT in lymphoma. Eur J Nucl Med Mol Imaging 41:1004–1027

    Article  PubMed  Google Scholar 

  3. Stevens WB, van Krieken JH, Mus RD, Arens AI, Mattijssen V, Oosterveld M et al (2012) Centralised multidisciplinary re-evaluation of diagnostic procedures in patients with newly diagnosed Hodgkin lymphoma. Ann Oncol 23(10):2676–2681

    Article  CAS  PubMed  Google Scholar 

  4. Specht L, Raemaekers J (2007) Do we need an early unfavorable (intermediate) stage of Hodgkin’s lymphoma? Hematol Oncol Clin N Am 21(5):881–896

    Article  Google Scholar 

  5. Noordijk EM, Carde P, Dupouy N (2006) Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24:3128–3135

    Article  PubMed  Google Scholar 

  6. Hoerni B, Orgerie MB, Eghbali H, Blanc CM, David B, Rojouan J et al (1988) New combination of epirubicin, bleomycin, vinblastine and prednisone (EBVP II) before radiotherapy in localized stages of Hodgkin’s disease. Phase II trial in 50 patients. Bull Cancer 75(8):789–794

    CAS  PubMed  Google Scholar 

  7. Pavlovsky S, Schvartzman E, Lastiri F (1997) Randomized trial of CVPP for three versus six cycles in favorable- prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin’s disease. J Clin Oncol 15:2652–2658

    CAS  PubMed  Google Scholar 

  8. Wasserman TH, Petroni GR, Millard F (1999) Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized stages of Hodgkin’s disease and unfavorable prognostic features: a phase II cancer and leukemia group B study. Cancer J 86:1590–1595

    Article  CAS  Google Scholar 

  9. Klimm B, Goergen H, Fuchs M, von Tresckow B, Boll B, Meissner J et al (2013) Impact of risk factors on outcomes in early-stage Hodgkin’s lymphoma: an analysis of international staging definitions. Ann Oncol 24(12):3070–3076

    Article  CAS  PubMed  Google Scholar 

  10. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C (1975) Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36(1):252–259

    Article  CAS  PubMed  Google Scholar 

  11. Canellos GP, Niedzwiecki D (2002) Long-term follow-up of Hodgkin’s disease trial. N Engl J Med 346(18):1417–1418

    Article  PubMed  Google Scholar 

  12. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM et al (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 21(4):607–614

    Article  CAS  PubMed  Google Scholar 

  13. Le Maignan C, Desablens B, Delwail V (2004) Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. Blood 103:58–66

    Article  PubMed  Google Scholar 

  14. Thomas J, Ferme C, Noordijk E (2007) Results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma. Haematologica 92(ABS):27

    Google Scholar 

  15. Borchmann P, Diehl V, Goergen H (2009) Combined modality treatment with intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavourable Hodgkin lymphoma (HL): final analysis of the German Hodgkin Study Group (GHSG) HD11 trial. Blood 114(abs):299–300

    Google Scholar 

  16. Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD et al (2013) Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 31(6):684–691

    Article  PubMed Central  PubMed  Google Scholar 

  17. Engert A, Borchmann P, Plütschow A, Fuchs M, Markova J, Lohri A et al (2009) Treatment with 2 cycles of BEACOPPesc followed by 2 cycles of ABVD and IF-RT is superior to 4 cycles of ABVD and IF-RT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Onkologie 32(Suppl 4):1–254

    Google Scholar 

  18. Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y et al (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79(3):270–277

    Article  PubMed  Google Scholar 

  19. Hasenclever D, Loeffler M, Diehl V (1996) Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin’s disease. German Hodgkin’s Lymphoma Study Group. Ann Oncol 7:95–98

    Article  PubMed  Google Scholar 

  20. von Tresckow B, Plutschow A, Fuchs M, Klimm B, Markova J, Lohri A et al (2012) Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30(9):907–913

    Article  Google Scholar 

  21. Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F et al (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 357(19):1916–1927

    Article  CAS  PubMed  Google Scholar 

  22. Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M et al (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21(19):3601–3608

    Article  PubMed  Google Scholar 

  23. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 22(14):2835–2841

    Article  PubMed  Google Scholar 

  24. Anselmo AP, Cavalieri E, Osti FM, Cantonetti M, De Sanctis V, Alfo M et al (2004) Intermediate stage Hodgkin’s disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy. Anticancer Res 24(6):4045–4050

    CAS  PubMed  Google Scholar 

  25. Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van ’t Veer MB, Lybeert ML et al (2003) Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 348(24):2396–2406

    Article  PubMed  Google Scholar 

  26. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D et al (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348(24):2386–2395

    Article  CAS  PubMed  Google Scholar 

  27. Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H et al (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112(10):3989–3994

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Laskar S, Gupta T, Vimal S, Muckaden MA, Saikia TK, Pai SK et al (2004) Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 22(1):62–68

    Article  CAS  PubMed  Google Scholar 

  29. Pavlovsky S, Maschio M, Santarelli MT (1988) Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin’s disease. J Natl Cancer Inst 80:1466–1473

    Article  CAS  PubMed  Google Scholar 

  30. Aviles A, Delgado S (1998) A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin’s disease with bulky disease. Clin Lab Haematol 20(2):95–99

    Article  CAS  PubMed  Google Scholar 

  31. Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J et al (2002) Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol 20(18):3765–3771

    Article  PubMed  Google Scholar 

  32. Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C et al (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104(12):3483–3489

    Article  CAS  PubMed  Google Scholar 

  33. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN et al (2012) ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 366(5):399–408

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA et al (2005) Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23(21):4634–4642

    Article  CAS  PubMed  Google Scholar 

  35. Raemaekers JM, Andre MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E et al (2014) Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32:1188–1194

    Article  PubMed  Google Scholar 

  36. Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M et al (2013) An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol 24(12):3065–3069

    Article  CAS  PubMed  Google Scholar 

  37. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA (2002) Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 20(3):630–637

    Article  PubMed  Google Scholar 

  38. Meyer RM, Hoppe RT (2012) Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy. Blood 120(23):4488–4495

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Meyer RM (2014) Limited-stage Hodgkin lymphoma: managing uncertainty. J Clin Oncol 32:1180–1182

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Radboud University Medical Center, Geert Grooteplein Zuid 8, Nijmegen, 6525GA, The Netherlands

    John M. M. Raemaekers MD, PhD

  2. Department of Internal Medicine I, German Hodgkin Study Group (GHSG), University Hospital of Cologne, Kerpener Strasse 62, Cologne, 50937, Germany

    Andreas Engert

Authors
  1. John M. M. Raemaekers MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Engert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John M. M. Raemaekers MD, PhD .

Editor information

Editors and Affiliations

  1. Universitätsklinikum Köln Klinik I für Innere Medizin, Köln, Germany

    Andreas Engert

  2. Memorial Sloan - Kettering Cancer Center, New York, New York, USA

    Anas Younes

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing

About this chapter

Cite this chapter

Raemaekers, J.M.M., Engert, A. (2015). Treatment of Early Unfavorable HL. In: Engert, A., Younes, A. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-12505-3_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-12505-3_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-12504-6

  • Online ISBN: 978-3-319-12505-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation